Trial Profile
A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin 5 mg and Empagliflozin 25 mg or Dapagliflozin 10 mg After Oral Administration in Healthy Male Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2019
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Evogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Dong-A Pharmaceutical
- 08 Apr 2019 Status changed from active, no longer recruiting to completed.
- 13 Dec 2018 New trial record